THERAPY DOSSIER · th-e6f6f09c18b2

Nutlin-3a (cis-imidazoline MDM2 antagonist)

Drug · No confident ChEMBL match for nutlin-3a specifically (nearest clinical analogue IDASANUTLIN/RG-7388); MDM2-p53 antagonist

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No confident ChEMBL match for nutlin-3a specifically (nearest clinical analogue IDASANUTLIN/RG-7388); MDM2-p53 antagonist
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22297670 ↗2012Mixed findings

MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.

MouseIschaemia-reperfusionRenalC57BL/6 wild-type and p53 knockoutIntraperitoneal

Model: Postischaemic (ischaemia-reperfusion) acute kidney injury

Nutlin-3a impaired tubular cell regeneration in a p53-dependent manner, but also prevented tubular necrosis by suppressing early sterile inflammation in a p53-independent manner, indicating that MDM2 has both proinflammatory and pro-regenerative roles in acute kidney injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…